Skip to main content
ADCT
NYSE Life Sciences

Q3 Revenue Jumps 33% to $21M as Restructuring Extends Cash Runway Into 2029

Tom Rudovsky · Reported by PR Newswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.58
Mkt Cap
$201.715M
52W Low
$0.78
52W High
$4.98
52W Position info
103% above low
Off High info
68% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ADCT has more than doubled off its 52-week low of $0.78.

Summary

Net product revenue rose to $21.7 million from $15.8 million a year ago on higher volume, and the net loss narrowed to $25.3 million ($0.16 per share) from $41.0 million ($0.30), with an adjusted loss per share of 6 cents. Total operating expenses fell 24% to $36.1 million as R&D dropped to $14.7 million from $26.8 million after discontinued programs. Cash stood at $189.2 million on September 30, and management reiterated a runway into 2029 following the October restructuring that brought in an $86.6 million PIPE and cut term-loan principal to $50 million. The Japan path is advancing: partner Tanabe filed a marketing authorization application and sublicensed commercialization to Nippon Shinyaku, which supports milestone payments. The overhang remains LOTIS-5 — the FDA raised serious benefit-risk concerns at the pre-sBLA meeting in August, and full Phase 3 data plus five oral presentations land at ASH in December, the key read for whether accelerated approval holds.

At the time of this announcement, ADCT was trading at $1.58 on NYSE in the Life Sciences sector, with a market capitalization of approximately $201.7M. The 52-week trading range was $0.78 to $4.98. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

ADCT - Latest Insights

ADCT
Nov 09, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.67 info
Change: -$0.0773 (-4%) info
Market Cap: $201.715M info
ADCT
Nov 04, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $1.67 info
Change: -$0.0513 (-3%) info
Market Cap: $201.715M info
ADCT
Nov 03, 2026, 5:02 PM EST
Filing Type: S-4
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $1.67 info
Change: +$0.1187 (+8%) info
Market Cap: $201.715M info
ADCT
Oct 13, 2026, 6:26 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.82
Real-time Price: $1.67 info
Change: -$0.1513 (-8%) info
Market Cap: $201.715M info
ADCT
Oct 08, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $1.67 info
Change: +$0.3387 (+25%) info
Market Cap: $201.715M info